Literature DB >> 30531631

Is the Medial Sural Artery Perforator Flap a New Workhorse Flap? A Systematic Review and Meta-Analysis.

David A Daar1, Salma A Abdou1, Joshua M Cohen1, Stelios C Wilson1, Jamie P Levine1.   

Abstract

BACKGROUND: The medial sural artery perforator flap offers thin, pliable tissue with a relatively long pedicle and low donor-site morbidity. This study explores the characteristics and uses of the medial sural artery perforator flap along with postoperative outcomes and complications.
METHODS: A systematic literature review was performed using PubMed, Embase, and Cochrane Central Register of Controlled Trials to identify all cases of medial sural artery perforator flap reconstruction. Descriptive and meta-analyses were performed on pooled outcomes. Multivariate logistic regression identified factors associated with increased complication rates.
RESULTS: Thirty-five studies encompassing 526 medial sural artery perforator flaps were included for analysis. The most common reasons for surgery were oncologic (47.6 percent) and traumatic injuries (31.8 percent). The oral cavity was the most common recipient location (45.5 percent). Average flap dimensions were 6.0 ± 2.3 cm × 9.8 ± 3.6 cm, with an average pedicle length of 10.1 ± 6.6 cm. Meta-analysis revealed an overall complication rate of 14.3 percent (Q value = 22.16; p = 0.877; I(2)= -39.9). Use of chimeric medial sural artery perforator flaps was associated with significantly higher rates of complications (OR, 3.92; p = 0.039; 95 percent CI, 1.10 to 13.89). The majority of flap donor sites were closed primarily (68 percent) versus 32 percent that were covered with split-thickness skin grafts. A flap width greater than 5.75 cm had an odds ratio of 5.3 (95 percent CI, 1.3 to 21.8; p = 0.014) of having a donor-site complication if closed primarily.
CONCLUSIONS: The medial sural artery perforator flap offers thin, pliable tissue with a relatively long pedicle and has minimal donor-site morbidity when the donor site is managed appropriately. As such, it should be considered a workhorse flap for both head and neck and extremity reconstruction.

Entities:  

Mesh:

Year:  2019        PMID: 30531631     DOI: 10.1097/PRS.0000000000005204

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  7 in total

1.  Utility of preoperative colour flow Doppler assessment of perforator anatomy in medial sural artery perforator (MSAP) free flaps.

Authors:  Ben J Steel; Darpan Mehta; Michael Nugent; Ajay Wilson; Andrew Burns
Journal:  Oral Maxillofac Surg       Date:  2022-08-18

2.  The Medial Sural Artery Perforator Flap: A Historical Trek from Ignominious to "Workhorse".

Authors:  Geoffrey G Hallock
Journal:  Arch Plast Surg       Date:  2022-04-06

3.  Split median superficial sural artery perforator (MSSAP) flap and medial sural artery perforator (MSAP) flap for posterior thigh sarcoma reconstruction.

Authors:  Natalia Mazur; Rik Osinga; Steven Lo
Journal:  BMJ Case Rep       Date:  2020-02-05

Review 4.  [Research progress of clinical application of medial sural artery perforator flap].

Authors:  Jie Fang; Buguo Chen; Yao Wu; Zhaolin Tang; Fei Ren; Wenlong Zhang
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2021-04-15

5.  Extended medial sural artery perforator free flap for groin and scrotal reconstruction.

Authors:  Chad M Teven; Jason W Yu; Lee C Zhao; Jamie P Levine
Journal:  Arch Plast Surg       Date:  2020-04-08

Review 6.  Do medial sural artery perforator flaps have better clinical outcomes compared to the rectus abdominis perforator (DIEAP) flap in reconstruction of glossectomy defects? A Prisma guided meta-analysis.

Authors:  Rathindra Nath Bera; Preeti Tiwari
Journal:  Ann Maxillofac Surg       Date:  2021-07-24

7.  Perforator-based Adipofascial Flaps and ADM: A Novel Combined Approach to Distal Lower Extremity Defects.

Authors:  Luigi Losco; Simone Sereni; Dicle Aksoyler; Davide Spadoni; Alberto Bolletta; Emanuele Cigna
Journal:  Plast Reconstr Surg Glob Open       Date:  2022-02-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.